Finnish group Huhtamaki has lowered its forecast for the full year following flat profits and a decline in earnings per share in the first eight months of 1994. Sales are reduced by 500 million markka ($103.7 million) to 8.5 billion markka ($1.8 billion). It is expected that EPS will be lower than the 133.59 markka achieved last year. Pretax profits will be flat at around 506 million markka.
The company is blaming a 15% rise in the markka against the US dollar for the changes. Huhtamaki's chief executive, Timo Peltola, is cautiously optimistic about an improvement in key markets, and results from its pharmaceutical unit Leiras were said to be satisfactory, according to the Financial Times.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze